These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23781656)

  • 1. Post marketing surveillance of sublingual buprenorphine naloxone combination tablets.
    Ray R; Vaswani M; Deb KS; Sethi H; Chopra A; Kishore N; Goyal R
    Indian J Physiol Pharmacol; 2012; 56(4):359-66. PubMed ID: 23781656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance of buprenorphine.
    Ray R; Pal H; Kumar R; Maulick P; Mangla R
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):615-9. PubMed ID: 15362084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.
    Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R
    Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
    Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
    J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
    Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
    Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL
    J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.